BIVI — BioVie Inc.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 14
- Website: https://bioviepharma.com
Latest SEC filings for BIVI
- 424B5 — 2026-09-14
- 8-K — 2026-09-14
- S-1/A — 2026-08-14
- 10-K — 2026-08-13
- S-1/A — 2026-08-06
- 8-K — 2026-08-06
- S-1/A — 2026-07-31
- S-1 — 2026-07-17
- S-3 — 2026-06-18
- 10-Q — 2026-05-11
Latest BIVI news
- — BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meeting (proactiveinvestors.com)
- — BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting (globenewswire.com)
Educational tool only — not investment advice.